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ABSTRACT
A prospective study was conducted to determine the prevalence of colonisation by Pneumocystis
jirovecii in 80 consecutive patients who required bronchoscopy and bronchoalveolar lavage (BAL)
following suspicion of interstitial lung disease (ILD). The mtLSU rRNA gene of P. jirovecii was
identified by nested PCR in BAL samples. Patients with ILDs were divided into three groups: group
A comprised those with idiopathic interstitial pneumonias; group B comprised those with
sarcoidosis; and group C comprised those with other ILDs. The overall prevalence of P. jirovecii
carriage was 33.8%, with colonisation rates of 37.8%, 18.8% and 37% in groups A, B and C,
respectively (p not significant). There were more smokers among the carriers, but there were no
other significant differences between carriers and non-carriers. The high prevalence of P. jirovecii
carriers found among immunocompetent patients with ILDs in Spain suggests a possible role of
P. jirovecii in the natural history of these diseases.
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INTRODUCTION
Pneumocystis jiroveci (formerly Pneumocystis carinii
f. sp. hominis) [1] is an atypical fungus with
pulmonary tropism that is considered to be an
opportunistic fungal pathogen causing severe
pneumonia in immunocompromised individuals,
principally AIDS patients. However, cases of
Pneumocystis pneumonia have been described in
individuals without predisposing illness [2,3],
and an increasing number of reports have
described the occurrence of asymptomatic
pulmonary colonisation by P. jirovecii in immu-
nocompetent hosts with underlying pulmonary
disease [4–7]. Interstitial lung diseases (ILDs)
account for c. 15% of respiratory disease, and
are associated with a substantial degree of mor-
bidity and mortality [8]. ILDs include a heteroge-
neous group of disorders of the lower respiratory
tract, most with unknown causes, in which injury
to the lung parenchyma leads to a cascade of
inflammatory and immune processes that, in
many cases, cause lung fibrosis. The exact mech-
anism by which connective tissue proliferation
occurs in some cases is unknown, although
infectious agents have been implicated in the
pathogenesis of ILDs [9,10]. Thus, in animal
models, it has been demonstrated that low num-
bers of Pneumocystis organisms induce the activa-
tion of alveolar macrophages, increase levels of
pro-inflammatory interleukins, and cause changes
in pulmonary surfactant components [11,12]. This
pulmonary inflammation, together with the adap-
tive immune response triggered by alveolar injury
caused by Pneumocystis, could play a role in the
pathogenesis of ILDs and in the progression of the
disease to fibrosis.
The aim of the present study was to determine
the prevalence of P. jirovecii colonisation by using
PCR to detect P. jirovecii DNA in bronchoalveolar
lavage (BAL) fluid from a large population of
patients with ILD.
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PATIENTS AND METHODS
Patients
Between 2001 and 2003, 120 consecutive patients attending the
bronchoscopy unit with suspicion of ILDs were studied. A
complete clinical, functional and radiological evaluation was
made of all patients. Diagnostic bronchoscopy with BAL fluid
examination was also performed. Informed consent was
obtained from all patients included in the study. Exclusion
criteria were underlying malignant disease, autoimmune
disorders, immunosuppressive therapy (steroids and cytotoxic
treatment) and a final diagnosis that did not include ILD. None
of the patients was known to be positive for human immuno-
deficiency virus. The final study population included 80
newly diagnosed patients with untreated ILDs. The study
was approved by the hospital’s ethical committee.
Diagnostic criteria
For practical reasons, the patients were divided into three
groups: group A comprised patients with idiopathic interstitial
pneumonias; group B comprised patients with sarcoidosis; and
group C comprised patients with other ILDs. Group A patients,
according to the classification proposed by the American
Thoracic Society (ATS) and the European Respiratory Society
(ERS) Consensus [13], comprised: patients with idiopathic
pulmonary fibrosis, non-specific interstitial pneumonia, cryp-
togenic organising pneumonia, acute interstitial pneumonia,
desquamative interstitial pneumonia and lymphoid interstitial
pneumonia. In seven of the 18 patients with idiopathic pulmon-
ary fibrosis, the diagnosis was established by evidence of
interstitial pneumonia in histological lung specimens. In the
absence of histology, the diagnosis of idiopathic pulmonary
fibrosis was established according to the clinical diagnostic
criteria proposed by the ATS ⁄ERS Consensus Statement [14].
For all other disorders considered as interstitial idiopathic
pneumonias, the diagnosis was confirmed histologically. For
patients in group B, the diagnosis was based on histological
evidence of non-caseating granulomas in lung specimens for 13
of 16 patients, with the diagnosis established for the remaining
three patients by consistent clinical features and BAL fluid
analysis, according to the ATS ⁄ERS ⁄World Association of
Sarcoidosis and Other Granulomatous Disorders (WASOG)
guidelines [15]. Patients in group C had a range of disorders,
including Langerhans’ cell pulmonary histiocytosis, silicosis,
extrinsic allergic alveolitis, pulmonary alveoli calcification of
parathyroid origin, drug-induced pneumonitis, chronic eosino-
philic pneumonia, allergic bronchopulmonary aspergillosis,
diffuse alveolar haemorrhage and non-classified interstitial
pneumonia. Disorders with diffuse interstitial damage, but
with characteristic clinical features, were included as non-
classified interstitial pneumonia. For patients in group C
without histological confirmation, the final diagnosis was
established by criteria reported previously for each disease. In
all cases, other disorders with a similar clinical picture were
excluded.
Data and specimen collection
General data, including age, gender, smoking habit and
number of pack-years smoked, were recorded. Peripheral
blood lymphocytes and BAL specimens were obtained from
the patients.
Bronchoalveolar lavage procedure
Three 50-mL aliquots of sterile saline (0.9%w ⁄v) were instilled
in the third-generation bronchus of the middle lobe, lingula, or
the area containing most lung infiltrates, under local anaes-
thesia, with a fibreoptic bronchoscope (Type 40; Olympus,
Tokyo, Japan). Each aliquot was recovered immediately by
suction. Samples for bacterial, fungal and parasitological
analysis were transported immediately to the laboratory in
sterile containers. Total cells were counted with a Neubauer
haemocytometer counting chamber. Differential cell counts
were performed after staining with modified May–Giemsa–
Gru¨nwald (Diff-Quick) stains. Lymphocyte sub-populations
were analysed by immunocytochemical techniques with
monoclonal antibodies against CD4+ and CD8+ T-cells only
for those patients whose lymphocyte percentage was > 15%.
Two techniques were used to identify P. jirovecii in BAL
samples:
1. Conventional technique. Microscopy was performed using a
conventional stain and an immunofluorescence assay with
monoclonal antibodies against P. jirovecii (Dako, Glostrup,
Denmark).
2. Molecular analysis. DNA was extracted using a QIAamp
tissue kit (Qiagen, Hilden, Germany), and the pneumocys-
tis mitochondrial region (mtLSU rRNA) was amplified
using nested PCR [16]. Briefly, in the first amplification
round, external primers pAZ102 (5¢-GATGGCTGTTTCC-
AAGCCCA-3¢-E) and pAZ102-H (5¢-GTGTACGTT-
GACAAGTACTC-3¢) were used to give a 346-bp fragment.
The second round of amplification utilised the internal
primers pAZ102-X (5¢-GTGAAATACAAATCGGACTA-
GG-3¢) and pAZ102-Y (5¢-TCACTTAATATTAATTGGG-
GAGC-3¢) to give a 260-bp product. Both rounds comprised
40 cycles of amplification. The amplification products
were visualised by UV light following agarose gel
electrophoresis and staining with ethidium bromide.
Standard precautions and controls were included to pre-
vent false-positive reactions caused by contamination. All
experiments were performed at least twice.
Definition of a P. jirovecii carrier
A P. jirovecii carrier was defined as an individual without
P. jirovecii pneumonia from whom a BAL specimen was
obtained that contained P. jirovecii DNA detectable by nested
PCR in two independent analyses.
Statistical analysis
SPSS v. 12.0 (SPSS Inc., Chicago, IL, USA) was used for
analysis, with p £ 0.05 considered to be significant. Data were
expressed as means (SD) or medians with 25–75% interquar-
tile range in accordance with the normal or non-normal
distributions. Comparisons between carriers and non-carriers
were tested using chi-square or Fisher’s exact test for qualit-
ative variables, and Student’s t-test or Mann–Whitney U-test
for quantitative variables.
RESULTS
PCR for P. jirovecii was positive for 27 (33.8%)
patients (carriers) and negative for 53 (66.2%)
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patients (non-carriers). In seven (8.8%) carriers,
conventional techniques also yielded positive
results for P. jirovecii. The baseline characteristics
and lymphocyte counts of all patients are sum-
marised in Table 1. The carrier group had signi-
ficantly higher proportions of men and smokers
than the non-carrier group (p 0.04 and p 0.02,
respectively). The median total lymphocyte count
was significantly lower in carriers than in non-
carriers (p 0.04). Table 2 shows the numbers of
colonised and non-colonised patients in groups A,
B and C. There were no significant differences in
the prevalence of P. jirovecii colonisation between
the three groups (p 0.36).
No differences in gender or age were found
when carriers and non-carriers of each subgroup
were analysed, but more carriers were smokers,
and the median of the total lymphocyte counts
was lower for carriers than for non-carriers;
however, these differences were only statistically
significant in groups C and A (p 0.018 and p 0.03,
respectively).
In the overall group, the BAL parameters did
not differ significantly between carriers and non-
carriers, but the percentage of CD4+ T-cells and
the CD4 ⁄CD8 index were lower in carriers than in
non-carriers, although the differences did not
reach statistical significance (p 0.13 and p 0.07,
respectively; Table 3). The BAL analysis did not
differ significantly between carriers and non-
carriers in the subgroups.
None of the patients had received oral corti-
costeroids at the time of bronchoscopy. All
27 carrier patients were human immunodefi-
ciency virus-negative, and none developed Pneu-
mocystis pneumonia during a 1-year follow-up
period.
DISCUSSION
The present study found a high percentage
(33.8%) of P. jirovecii colonisation in patients with
ILDs, with no differences in the prevalence of
colonisation among different kinds of ILD. In the
absence of a reliable method for P. jirovecii cul-
ture, the use of PCR allowed the detection of low
levels of microorganisms in lung samples from
asymptomatic subjects. Early studies on post-
mortem lungs from immunocompetent individu-
als failed to detect Pneumocystis [17,18], although
more recent studies have demonstrated that
Pneumocystis DNA can be detected in healthy
infants and healthy adults [19,20].
Pneumocystis carriage has been shown to be
common in immunocompetent patients with
Table 1. Baseline characteristics of total population and
comparison of Pneumocystis jirovecii non-carriers and car-
riers
Total (n = 80) Non-carriers (n = 53) Carriers (n = 27) p
Median age,
years (range)
58 (42–68) 59 (42–70) 56 (41–70) 0.14a
Males, n (%) 53 (66.3) 31 (58.5) 22 (81.5) 0.04b
Smokers, n (%) 45 (56.3) 25 (47.2) 20 (74.1) 0.02b
Median
lymphocytes ⁄
mm3 (range)
2200 (1520–3000) 2455 (1800–3500) 1850 (1400–2402) 0.04a
aStudent’s t-test.
bChi-square test.
p < 0.05 was considered to be statistically significant.
Table 2. Number of Pneumocystis jirovecii non-carriers and
carriers according to the interstitial lung disease groups
Non-carriers
n = 53 (66.2%)
Carriers
n = 27 (33.8%)
Group A: IIPs
IPF 13 5
NSIP 2 2
COP 5 5
AIP 0 2
DIP 2 0
LIP 1 0
Total (n = 37) 23 (62.2%) 14 (37.8%)
Group B: sarcoidosis (n = 16) 13 (81.3%) 3 (18.8%)
Group C: other ILDs
Pulmonary Langerhans’ cell histiocytosis 1 2
Silicosis 1 1
Pulmonary calcification 1 0
Extrinsic allergic alveolitis 2 0
Amiodarona-induced pneumonitis 2 1
Chronic eosinophilic pneumonia 0 2
Allergic bronchopulmonary aspergillosis 1 0
Diffuse alveolar haemorrhage 1 0
NCIPs 8 4
Total (n = 27) 17 (63%) 10 (37%)
ILD, interstitial lung disease; IIPs, idiopathic interstitial pneumonias; IPF, idiopathic
pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; COP, cryptogenic
organising pneumonia; AIP, acute interstitial pneumonia; DIP, desquamative
interstitial pneumonia; LIP, lymphoid interstitial pneumonia; NCIPs, non-classified
interstitial pneumonias.
Table 3. Bronchoalveolar lavage differential cell counts in
non-carriers and carriers
Non-carriers n = 53/46a Carriers n = 27/26a p
Macrophages, % (range) 56 (28–78) 62 (33–78) 0.71
Lymphocytes, % (range) 29 (10–48) 21 (7–36) 0.09
Neutrophils, % (range) 4 (1–12) 3 (2–16) 0.84
Eosinophils, % (range) 1 (0–5) 1 (0–6) 0.75
T-lymphocyte
sub-populations
n = 25 n = 9
CD4, % (range) 51 (22–79) 32 (15–48) 0.13
CD8, % (range) 38 (16–65) 42 (28–64) 0.62
CD4 ⁄CD8 index 2 (0.4–4) 0.5 (0.2–1.3) 0.07
aNumber of patients in which BAL was valid for cellular count.
Values are median (25–75% interquartile range).
p < 0.05 was considered to be statistically significant (Mann–Whitney U-test).
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underlying pulmonary disease. In patients with
chronic pulmonary disease, the apparent rate of
P. jirovecii colonisation ranges from 7% to 41%,
depending upon the precise disease studied and
the diagnostic technique used [4,7,16]. A recent
study has suggested that oral glucocorticoid
therapy is an independent risk-factor for coloni-
sation [21], but none of the patients included in
the present study had received oral corticoster-
oids at the time of bronchoscopy, and only two
patients had been prescribed inhaled steroids.
There are only two previous reports regarding
the prevalence of P. jirovecii in ILDs, as a sub-
group of respiratory diseases [5,6], and the pre-
sent study is the first to include a relatively large
number of patients with ILDs. A predominance of
males was observed among P. jirovecii carriers,
associated with a higher percentage of smokers in
the carrier group. Previous studies have demon-
strated that cigarette consumption is an inde-
pendent risk-factor for Pneumocystis colonisation
in subjects infected with human immunodefi-
ciency virus [22]. The exact mechanism by which
smoking facilitates the infection is unknown, but
it has been demonstrated that mucociliary clear-
ance and pulmonary surfactant are deficient in
smokers [23,24]. Thus, smoking could modify the
pulmonary host defence against the microorgan-
ism, thereby facilitating colonisation.
In carrier patients, the peripheral blood lym-
phocyte levels were lower than in non-carriers.
These results differ from those in a study of
patients with chronic obstructive pulmonary dis-
ease, which showed a higher total lymphocyte
count in carrier patients [25]. This finding might
be related to the frequent infections caused by
other pathogens in patients with chronic obstruc-
tive pulmonary disease. In the present study, the
reduced lymphocyte count or lymphopenia
observed in colonised patients might facilitate
the carrier status [26].
The differential cell counts in the BAL fluid
revealed a low CD4 ⁄CD8 ratio in carrier patients,
mainly because of a decreased percentage of CD4+
T-cells. Previous studies have demonstrated a
correlation between a specific BAL fluid cellular
profile and the presence of infection caused by
Pneumocystis. A study performed with simian
immunodeficiency virus-infected macaques colo-
nised by Pneumocystis found that infected animals
had an increased CD8+ T-cell count in BAL fluid
(>90%), compared with simian immunodeficiency
virus-infected animals without Pneumocystis colo-
nisation [27]. In the same study, BAL fluid neutro-
philia was correlated with progression of disease.
A methodological limitation of the present
study was the absence of a control group, since
obtaining lung samples by invasive techniques,
such as fibrobronchoscopy, from healthy individ-
uals is not ethically acceptable. Nevertheless,
other studies that have evaluated the implications
of sub-clinical P. jirovecii infection in the patho-
genesis of chronic lung disease have suggested
that P. jirovecii colonisation could accelerate the
progression of the bronchial obstruction in chro-
nic obstructive pulmonary disease [28], and that
there is a relationship between asymptomatic
colonisation and the presence of small-cell lung
carcinomas [29].
The present study detected a high prevalence of
P. jirovecii carriers among a large number of
immunocompetent patients with ILDs, but no
differences were found in the rates of colonisation
according to each individual pathology. More
extensive studies will be necessary to determine
whether the increased inflammatory response
caused by P. jirovecii in the lung parenchyma is
linked to the development and ⁄ or the progression
of these diseases.
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